CN117210420A - Bacterial laccase allosteric and preparation method thereof - Google Patents
Bacterial laccase allosteric and preparation method thereof Download PDFInfo
- Publication number
- CN117210420A CN117210420A CN202311195363.0A CN202311195363A CN117210420A CN 117210420 A CN117210420 A CN 117210420A CN 202311195363 A CN202311195363 A CN 202311195363A CN 117210420 A CN117210420 A CN 117210420A
- Authority
- CN
- China
- Prior art keywords
- laccase
- allosteric
- bacterial
- bacterial laccase
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010029541 Laccase Proteins 0.000 title claims abstract description 106
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 43
- 230000003281 allosteric effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 28
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- 238000012217 deletion Methods 0.000 claims abstract description 11
- 230000037430 deletion Effects 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 9
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 239000013612 plasmid Substances 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 8
- 239000013599 cloning vector Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 108700010070 Codon Usage Proteins 0.000 claims description 2
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 20
- 229940088598 enzyme Drugs 0.000 description 26
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 10
- 229960002064 kanamycin sulfate Drugs 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 102000043368 Multicopper oxidase Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108700020788 multicopper oxidase Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710180995 Endonuclease 1 Proteins 0.000 description 1
- 101710181043 Endonuclease 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000004076 pulp bleaching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0061—Laccase (1.10.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03002—Laccase (1.10.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application discloses a bacterial laccase allosteric and a preparation method thereof, wherein the bacterial laccase allosteric also discloses a corresponding nucleic acid sequence and engineering bacteria containing the sequence; according to the application, by deleting the corresponding sequence or the deletion fragment at a specific sequence site, more specifically deleting the sequence forming the MR helix and the R-loop structure in the sequence, the activity of the obtained bacterial laccase is enhanced, and the expression quantity is effectively improved.
Description
Technical Field
The application relates to the fields of genetic engineering and enzyme engineering, in particular to a bacterial laccase allosteric with high expression level and a preparation method thereof.
Background
Laccase, a polyphenol oxidase enzyme containing multiple copper ions, exists mainly in the form of monomeric glycoproteins. Laccase has a wide catalytic substrate spectrum, can catalyze and oxidize phenols and aromatic compounds, and the only product after the reaction is water, so that the laccase is an environment-friendly catalyst in nature. In addition, the enzyme can be used for being cooperated with other enzymes, and is the most potential industrial enzyme preparation. Laccase can be used in the industrial fields of food processing, pulp bleaching, green synthesis and the like, and has wide application value. In nature, laccase is widely available, and laccase functions similarly from different species are found in fungi, bacteria, plants and animals. The laccase from bacteria has the advantages of short growth period, good thermal stability, wide pH range and the like compared with other laccase, and is more suitable for large-scale industrial application. However, the current methods for improving the activity and the expression level of laccase from bacterial sources are few, so that the method has important research significance and practical application value for the research of improving the activity and the expression level of laccase from bacterial sources. The directional modification strategy is means for carrying out multiple rounds of accumulation, continuous mutation, expression and screening on the protein, so as to guide the expression of the protein to a direction required by people. The method is the most widely applied protein transformation means at present, but has the advantages of long screening time, large workload, random unpredictable mutation and influence on the protein transformation efficiency. Along with the rapid development of structural biology and computational biology, the computer simulation auxiliary enzyme modification predicts the gene modification range and site by analyzing the relation among protein sequence, structure and function, can remarkably increase the proportion of effective allosteric and greatly shortens the experimental period. Many studies have shown that by computer-aided rational design, enzymatic molecular engineering can significantly improve the catalytic properties of enzymes and can significantly reduce the effort required to create and screen an allosteric library.
However, site-directed engineering techniques have focused only on small-scale engineering of protein molecules, particularly point mutations. With the deep understanding of protein folding and protein structure, the improvement of protease domain genes, enzyme activity, expression level and other characteristics of the modified protease are found to be improved obviously. At present, the laccase structural domain genes are changed in a computer-aided design manner mainly aiming at dehydrogenase, cellulase, mannanase and the like, and at present, patent reports for improving laccase activity and expression quantity through gene structural domain optimization transformation still exist.
Disclosure of Invention
The application provides a bacterial laccase allosteric, related sequences, engineering bacteria and a preparation method thereof.
The application is realized by the following technical scheme.
A bacterial laccase variant having an amino acid sequence comprising at least one deletion fragment compared to the amino acid sequence of a wild-type bacterial laccase as set forth in SEQ ID No. 1; after the deletion fragment was removed, the steric structure of Cu1 formed by His443, cys500 and His505 was not altered.
Preferably, the deletion fragment is an amino acid sequence forming an R-loop structure or MR helix in a wild-type bacterial laccase.
Preferably, the position of the deletion fragment is any one of positions 61-68, 128-140, 198-206, 256-264, 313-322 or 373-385 of the amino acid sequence of the wild-type bacterial laccase shown in SEQ ID NO. 1.
Preferably, the amino acid sequence of the bacterial laccase allosteric is any one of the sequences shown in SEQ ID NO.2-SEQ ID NO. 9.
The application also provides a nucleic acid sequence for encoding the bacterial laccase allosteric.
Preferably, the nucleic acid sequence is any one of the sequences shown in SEQ ID NO.11-SEQ ID NO. 18.
The application also provides engineering bacteria which contain the nucleic acid sequence and/or the bacterial laccase allosteric variant.
The application also provides a preparation method of the bacterial laccase allosteric, which comprises the following steps:
step 1, acquiring a sequence: taking the crystal structure of laccase CueO from escherichia coli as a prototype, and carrying out protein aided design by using Autodock Vina and RosettaFold, pyMOL, procheck software to obtain bacterial laccase allosteric, sequence structure and gene sequence;
step 2, synthesizing laccase genes: according to the codon preference of the host strain, synthesizing a cloning vector plasmid pUC-GW-Kan containing the gene of the bacterial laccase allosteric body optimized by the preferred codon and the host strain thereof;
step 3, extracting laccase gene templates: culturing and collecting host strains containing cloning vector plasmids, extracting plasmids, and obtaining a vector pUC-GW-Kan containing a gene template of a bacterial laccase variant;
step 4, constructing a recombinant vector: connecting a bacterial laccase allosteric gene with a pET28a+ plasmid by an enzyme cutting connection method to construct a recombinant vector, so as to obtain the recombinant vector;
step 5, constructing a recombinant strain: transforming the recombinant vector into competent cells of the escherichia coli to obtain recombinant strains;
step 6, induction culture: inducing and culturing the recombinant strain with isopropyl-beta-D-thiogalactoside (IPTG), adding copper sulfate (CuSO 4), further culturing, and extracting protein;
step 7, laccase activity determination: laccase activity was determined using ABTS method.
Preferably, the E.coli strain of step 5 is E.coli BL21 DE3 strain, also known as E.coli BL21 (D3) strain.
The catalytic mechanism of laccase is that Cu1 is positioned in the active center of enzyme and can be combined with a substrate to become a receiver of electrons, and the electrons are transferred to Cu2 to reduce oxygen molecules in the active center into water. Therefore, the application selects the sites far away from Cu1 ion for deletion, such as 61-68, 128-140, 198-206, 256-264 and 313-322; the following sites can be obtained by trial and error according to a computer simulation model, and the active center cannot be affected by deletion. The existence of R-loop can affect a methionine rich helix structure (MR), and the MR helix is pulled together through hydrophilic and hydrophobic interaction to block a substrate from entering a channel of an active center, the MR helix is deleted, R-loop (amino acid sequence is 373-385) is deleted on the basis of the MR helix, and a transport channel is opened, so that a macromolecular substrate can enter a butt joint part. At the same time, the butt joint area is not affected, so the application simplifies the structure. In addition, the application also largely tries to delete the 198-206 amino acids, and opens the binding position further, which is more favorable for the binding of macromolecular substrates, but can have adverse effects on the binding of small molecular substrates.
As with other multicopper oxidases, the important feature of the crystal structure of laccase CueO is that four Cu ions are arranged at two positions, and are classified into three types, cu1 (located between the spaces formed by His443, cys500 and His 505), cu2 and two Cu3, the latter three forming a TNC three cluster structure. Cu1 is positioned at the substrate binding site, and when the substrate is oxidized, electrons can be transferred to Cu1, and then the electrons are transferred from the mononuclear central channel to the oxygen molecule binding center by the Cu 1. Cu2 and Cu3 are positioned at the oxygen molecule combination part, the part is a TNC three-cluster structure, and the oxygen molecule finally accepts electrons to generate water. The conventional method mainly deletes the C-terminal and/or N-terminal of the protease sequence, but cannot be adopted because the C-terminal and N-terminal of laccase CueO are main constituent amino acids constituting the activity of the laccase. The principle of the application in deletion is to keep the active center and the space of Cu1, cu2 and Cu3 unchanged, so as to prevent the loss of enzyme function. It is widely accepted that amino acids spatially distant from the active center have little effect on enzyme function. See, in particular: wang, H., liu, X., zhao, J.et al crystal structures of multicopper oxidase CueO G K variant: structural basis ofthe increased laccase activity. SciRep 8,14252 (2018).
R-loop can form a hydrophobic pocket with the MR helix, hydrophobic interactions occur primarily between Leu367, aal375, met376 of the MR helix in domain III, met303, met305 and Ile307 on the R loop in domain II, and Val207 and Phe210 of helix α1 and the adjacent loop of domain II. Hydrogen bonding exists between the backbone amide of Gly304 on the R ring in domain II and the backbone carbonyl of Ala375 of the MR helix in domain III. The application omits the MR helix, and in order to further enlarge the hydrophobic pocket and facilitate the substrate to enter the catalytic site, the application appropriately omits the R-loop.
The beneficial technical effects of the application are as follows:
according to the application, by deleting the corresponding sequence (deletion fragment) at a specific sequence site, more specifically deleting the sequence forming the MR helix and the R-loop structure in the sequence, the activity of the obtained bacterial laccase is enhanced, and the expression quantity is effectively improved.
Drawings
FIG. 1 is a agarose gel electrophoresis diagram of a mutant gene expression vector construction;
FIG. 2 is the construction of a wild-type cellular laccase CueO recombinant vector;
FIG. 3 is a protein concentration standard graph;
FIG. 4 is a graph showing the expression level of laccase allosteric and the fold ratio of wild type laccase;
FIG. 5 is a fold plot of laccase allosteric activity versus wild type laccase.
Detailed Description
The application will be further described with reference to the accompanying drawings and detailed description below:
the application aims to provide a series of CueO laccase with high expression level, which contains the amino acid sequences of SEQ ID NO. 2-9. Aims at providing a series of laccase allosteric and preparation method and application of the laccase allosteric and expression strain thereof, comprising the following steps:
step 1, taking a crystal structure of laccase CueO from escherichia coli as a prototype, carrying out aided protein design by using software such as Autodock Vina, rosetta Fold and PyMOL, procheck, and obtaining laccase allosteric structure and gene sequence according to a computer simulation result and a laccase catalysis mechanism.
Step 2, synthesizing laccase genes: carrying out gene synthesis in a gene synthesis company to obtain a cloning vector plasmid pUC-GW-Kan containing laccase genes optimized by preferred codons and host strains thereof;
step 3, extracting laccase gene templates: culturing and collecting host strains containing cloning vector plasmids, extracting plasmids, and obtaining a vector pUC-GW-Kan containing laccase gene templates;
step 4, constructing a recombinant vector: digesting pUC-GW-Kan and pET28a+ plasmids with restriction enzymes, recovering, and connecting with T4 ligase to construct a recombinant vector;
step 5, constructing a recombinant strain: transforming the recombinant vector into competent cells of escherichia coli BL21 to obtain recombinant strains;
step 6, induction culture: with IPTG and CuSO 4 Inducing and culturing recombinant strains, and extracting proteins;
step 7, laccase concentration determination: determining laccase concentration using Bradford protein concentration determination kit;
step 8, laccase activity determination: laccase activity was determined using ABTS method.
Further, the liquid medium in the step 3 is LB medium (containing 50. Mu.g/mL kanamycin sulfate): the ingredients of the preparation method are 10.0g of tryptone, 5.0g of yeast extract and 10.0g of sodium chloride, and 25g of LB broth culture medium powder is weighed and dissolved in 1L of water when in use.
Further, the plasmid extraction in the step 3 uses a plasmid extraction kit of Tiangen biochemical technology (Beijing) limited company, and the specific process is described according to the operation of the kit. The purity of the plasmid concentration box is measured by an ultra-micro ultraviolet spectrophotometer, and the plasmid concentration box is labeled and placed at the temperature of minus 20 ℃ for standby.
Further, the enzyme digestion system in the step 4 is as follows:
10 XNEB buffer | 5μl |
DNA | ≤1μg |
Endonuclease 1 | 1μl |
Endonuclease 2 | 1μl |
Sterilizing double distilled water | To 50 μl |
Incubation temperature | 37℃ |
Incubation time | 2h |
Finally, 10. Mu.l of 6X Gel loading buffer was added to the system to terminate the cleavage reaction;
the digested product was subjected to agarose gel electrophoresis at 110V for 45 minutes. The gel was cut and the correct strips (Shanghai Biotechnology Co., ltd.) were recovered according to the gel imaging results as shown in FIG. 1. Cloning laccase genes into pET28a+ plasmids by T4 ligase;
further, in the step 5, the recombinant vector described in the step 3 was transformed into the host strain BL21 (DE 3) by a chemical transformation method, and the transformed product was plated on LB (containing 50. Mu.g/mL kanamycin sulfate) plates and cultured overnight at 37℃to select positive clones. Picking single colony, extracting plasmid and carrying out colony PCR verification;
the PCR system is as follows:
Template | 0.5μl |
Forward Primer(10μM) | 1μl |
Reverse Primer(10μM) | 1μl |
10×EasyTaq Buffer | 2.5μl |
2.5mM dNTPs | 2μl |
EasyTaq DNA Polymerase | 0.25μl |
Nuclease-free Water | to 25μl |
the PCR procedure was as follows:
further, in the above-mentioned step 6, positive clones were picked up and inoculated into LB medium (containing 50. Mu.g/mL kanamycin sulfate) and cultured overnight at 37 ℃. Inoculating the overnight culture into 80mL LB culture medium (containing 50 μg/mL kanamycin sulfate), culturing under vigorous shaking (200 rpm) at 37deg.C until OD600 value of the bacterial liquid reaches about 0.6-0.8, adding IPTG and CuSO at certain concentration into fermentation system 4 Culturing at 37deg.C. Centrifuging at 8000rpm for 15min after induction, discarding supernatant, and collecting thallus; the cells were resuspended in Buffer A and PMSF and sonicated (3 s, 6s intermittent, 70% power, 90 cycles) and centrifuged at 8000rpm for 15min. Collecting supernatant and filtering with 0.45 μm filter membrane to obtain protein solution which is crude enzyme solution containing target protein CueO;
the Buffer a solution contained 20mM sodium phosphate, 500mM sodium chloride, 20mM imidazole, ph=7.3.
Further, the laccase protein concentration detection in step 7: preparing bovine serum albumin standard solutions with different concentrations, taking 200 mu L of Bradford solution and 20 mu L of standard protein solution, uniformly mixing and adding into an ELISA plate. Measurement at OD using a microplate reader 595 Absorbance at A of standard protein 595 The average value is on the ordinate, the corresponding protein concentration is on the abscissa, and a standard curve is established. By detecting the OD of the mixture of laccase protein and Bradford 595 Absorbance at which the concentration of laccase protein was determined.
Further, the enzyme activity in step 8 is defined as the amount of enzyme required to oxidize 1. Mu. Mol of ABTS per minute to convert to product is 1U. The absorbance change per minute is defined as an enzyme activity unit expressed by U/L as follows:
u=106×v total×n×Δa/(V enzyme×epsilon×Δt)
Wherein V is 1mL of the total reaction system, and ΔA=A 420 -A 0 The V enzyme is diluted enzyme liquid with a certain proportion, epsilon is the molar absorptivity of ABTS of 36,000, N is the dilution multiple of laccase, and DeltaT is the reaction time of 1min.
The reaction system is as follows:
ABTS method: the reaction system contains 1mmol/L ABTS,50mmol/L citric acid-phosphate buffer solution and 2mmol/L Cu 2+ The absorbance was measured rapidly at 420nm by 1mL total volume and 1min reaction at 55deg.C.
The formula of the citric acid-phosphate buffer solution is as follows: 2.4016g of citric acid was dissolved in 250mL of 1mol/L phosphate buffer, and 1L of 1mol/L phosphate buffer contained 132mL of 1mol/L potassium hydrogenphosphate solution and 868mL of mol/L potassium dihydrogenphosphate solution.
Example 1
Taking the crystal structure of laccase CueO of the source escherichia coli as a prototype, deleting partial amino acids with the amino acid sequence shown as SEQ ID NO.1 of the wild laccase by using molecular docking software Autodock Vina to obtain allosteric 1-8 laccase allosteric total; the specific amino acid sequence is shown as SEQ ID NO. 2-9; wherein the corresponding DNA sequence of the wild laccase is shown as SEQ ID NO.10, and the corresponding DNA sequences of the variants 1-8 are shown as SEQ ID NO. 11-18. And (3) carrying out homologous modeling on the deleted three-dimensional structure by adopting RosettaFold, and analyzing and evaluating a modeling result by using PyMOL software and Procheck software. Based on the above computer simulation results, the following variant in 8 was specifically obtained by combining deep analysis of laccase catalytic mechanism. As shown in Table 1 below, the numerical ranges in the table indicate that the site is absent, -indicating that the site is not absent.
TABLE 1 deletion sites of 8 allosteric variants
Example 2
Construction of a wild bacterial laccase CueO recombinant vector:
the synthesized vector bacteria were taken out and inoculated into LB medium (containing 50. Mu.g/mL kanamycin sulfate) and cultured overnight on a shaker at 37 ℃. And (3) extracting plasmids according to the operation instructions of a plasmid extraction kit after collecting thalli to obtain a vector containing wild bacterial laccase. The vector pUC-GW-Kan containing laccase gene and empty vector pET28a+ were digested singly by HindIII, digested for 2 hours at 37℃and the digested fragments were recovered by the product recovery kit. Then, the product is recovered by SacI single enzyme digestion, enzyme digestion is carried out for 2 hours at 37 ℃, and the target fragment is recovered by the DNA gel recovery kit through operations such as gel cutting. The laccase gene was then inserted into the pET28a+ plasmid by overnight ligation with T4 ligase at 16℃to obtain a recombinant vector, as shown in FIG. 2.
Example 3
Construction of bacterial laccase allosteric recombinant vector:
the vector bacteria containing the allosteric gene are taken out and inoculated into LB culture medium (containing 50 mug/mL kanamycin sulfate) for enrichment culture. Extracting plasmids according to the operation description of the plasmid extraction kit to obtain the vector containing laccase allosteric genes. The vector pUC-GW-Kan containing laccase genes and empty vector pET28a+ are digested by EcoRI and SalI, digested for 2 hours at 37 ℃, target fragments are recovered by using a DNA gel recovery kit through operations such as gel cutting, and then the laccase genes are inserted into pET28a+ plasmid by overnight connection of T4 ligase at 16 ℃ to obtain the recombinant vector.
Example 4:
construction of genetically engineered bacteria:
the recombinant plasmid was transformed into competent cells of E.coli BL21 (DE 3), and the transformed product was plated on LB (containing 50. Mu.g/mL kanamycin sulfate) plates and cultured at 37 ℃. Part of the positive clones were randomly picked and inoculated into liquid LB (containing 50. Mu.g/mL kanamycin sulfate) and cultured at 37℃and 200 rpm. And collecting thalli, extracting plasmids according to a plasmid extraction kit, and carrying out PCR verification. The verification primers were as follows:
Yack-pet28-M①F:AAGGGGTTATGGTAGTTATTG
Yack-pet28-M①R:GGTAGATTGCTGCGTAGTTC
Yack-pet28-M②F:CGATTAGAGACCCCAAGG
Yack-pet28-M②R:AGCGTGTTGCGTGTAAAT
Yack-pet28-cDNA①F:TGACCGAAGAAACCACCCT
Yack-pet28-cDNA①R:AGCCGTTCAGAAGTTGTAAGC
Yack-pet28-cDNA②F:TGGAGTTGAGCGGTCTTT
Yack-pet28-cDNA②R:CCAATACAGGGTGGTTTCTT
the first two pairs of primers (Yack-pet 28-M (1)/(2)) in the primers are matched with the sequence on the plasmid at least at one end and the accounting sequence of the bacterial laccase variant at the other end, so that detection is realized, and the functions of the two pairs of primers are the same. The two latter pairs of primers are only matched with the heterogeneous nucleic acid of the bacterial laccase, and are also used for detecting whether the engineering bacteria contain target genes.
The recombinant strain which is verified to be successful is stored in 25% glycerol pipe and is stored at-80 ℃.
Example 5
Laccase expression and concentration determination
The recombinant engineering bacteria obtained in example 4 were inoculated into LB medium (containing 50. Mu.g/mL kanamycin sulfate) and activated overnight at 37 ℃. The overnight culture was inoculated into 80mL of LB medium (containing 50. Mu.m)g/mL kanamycin sulfate), shaking vigorously (200 rpm) at 37deg.C until the OD600 of the bacterial liquid reaches about 0.6-0.8, adding inducer IPTG (final concentration 0.5 mM), and CuSO 4 (final concentration 1 mM), at 37℃for 72 hours. After the induction, absorbance at 600nm was measured and the bacterial solution was centrifuged at 8000rpm for 15 minutes, and the supernatant was discarded to collect the bacterial cells. The obtained protein liquid is crude enzyme liquid containing target protein through ultrasonic crushing, centrifugation and filtration. Detecting the crude enzyme liquid by SDS-PAGE, and determining the protein concentration by using a Bradford kit; the specific standard curve is shown in fig. 3; different protein concentrations in table 2 below were obtained according to different induction times.
TABLE 2 protein concentration
Example 6
Purification of laccase
The crude enzyme solution obtained in example 5 was purified according to the GE Healthcare nickel column protein purification instructions, and the effluent was collected. The crude enzyme solution and effluent were assayed by SDS-PAGE and the protein concentration was determined using the Bradford kit.
Example 7
Determination of laccase Activity:
in a citrate-phosphate buffer at pH6.4, 1mM ABTS was used as a substrate, and the reaction was carried out with an enzyme solution in a water bath at 55℃for 1min, and the absorbance at 420nm was measured after the reaction and the enzyme activity was calculated. One unit of enzyme activity is the enzyme required to oxidize 1. Mu. Mol of ABTS per minute.
The results show that laccase allosteric is expressed in IPTG and CuSO 4 The common induction is carried out for 72 hours, after the culture at the temperature of 200rpm and 37 ℃, the activity is 0.8 to 1.5 times of that of the wild laccase CueO, and the expression quantity is 0.9 to 10 times of that of the wild laccase CueO. Wherein the enzyme activity of the allosteric 4 can reach 323.8U/L, 1.5 times the CueO activity of the prototype laccase (see FIG. 5); the expression quantity can reach 2706.4mg/mL, which is 10 times of the expression quantity of the wild laccase CueO (see figure 4); specific values are shown in Table 3 below, and specifically, the expression level and enzyme activity of the corresponding strain construct are divided by the corresponding expression level and enzyme activity of the wild type to obtain corresponding multiples.
Table 3, expression levels of 8 types of allosteric and enzyme activities thereof are shown in comparison with wild type fold tables
All documents mentioned in this disclosure are incorporated by reference in this disclosure as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the application as defined in the appended claims.
Claims (7)
1. A bacterial laccase variant, characterized in that: the amino acid sequence of the bacterial laccase allosteric is shown as SEQ ID NO. 8.
2. The bacterial laccase variant according to claim 1, characterized in that: the deletion fragment is an amino acid sequence forming an R-loop structure or an MR helix in a wild bacterial laccase sequence.
3. A nucleic acid sequence encoding the bacterial laccase variant of any one of claims 1 or 2, characterized in that: the nucleic acid sequence is shown as SEQ ID NO. 17.
4. An engineering bacterium is characterized in that: the engineering bacterium contains the nucleic acid sequence of claim 3.
5. An engineering bacterium is characterized in that: the engineering bacterium contains the bacterial laccase allosteric according to any one of claims 1 to 2.
6. A method of preparing a bacterial laccase variant according to any one of claims 1 to 2, characterized in that it comprises the steps of:
step 1, acquiring a sequence: taking the crystal structure of laccase CueO from escherichia coli as a prototype, and carrying out protein aided design by using Autodock Vina and RosettaFold, pyMOL, procheck software to obtain bacterial laccase allosteric, sequence structure and gene sequence;
step 2, synthesizing laccase genes: according to the codon preference of the host strain, synthesizing a cloning vector plasmid pUC-GW-Kan containing the gene of the bacterial laccase allosteric body optimized by the preferred codon and the host strain thereof;
step 3, extracting laccase gene templates: culturing and collecting host strains containing cloning vector plasmids, extracting plasmids, and obtaining a vector pUC-GW-Kan containing a gene template of a bacterial laccase variant;
step 4, constructing a recombinant vector: connecting a bacterial laccase allosteric gene with a pET28a+ plasmid by an enzyme cutting connection method to construct a recombinant vector, so as to obtain the recombinant vector;
step 5, constructing a recombinant strain: transforming the recombinant vector into competent cells of the escherichia coli to obtain recombinant strains;
step 6, induction culture: inducing and culturing the recombinant strain by isopropyl-beta-D-thiogalactoside IPTG, adding copper sulfate for further culture and induction culture, and extracting protein;
step 7, laccase activity determination: laccase activity was determined using ABTS method.
7. The method for preparing bacterial laccase allosteric according to claim 6, wherein: the escherichia coli in the step 5 is escherichia coli BL21 DE3 strain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311195363.0A CN117210420A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311195363.0A CN117210420A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202111496402.1A CN113999826B (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111496402.1A Division CN113999826B (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117210420A true CN117210420A (en) | 2023-12-12 |
Family
ID=79931588
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311195365.XA Pending CN117210422A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195364.5A Pending CN117210421A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195368.3A Pending CN117210424A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195367.9A Pending CN117210423A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202111496402.1A Active CN113999826B (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195369.8A Pending CN117210425A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195362.6A Pending CN117210419A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195363.0A Pending CN117210420A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311195365.XA Pending CN117210422A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195364.5A Pending CN117210421A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195368.3A Pending CN117210424A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195367.9A Pending CN117210423A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202111496402.1A Active CN113999826B (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195369.8A Pending CN117210425A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
CN202311195362.6A Pending CN117210419A (en) | 2021-12-09 | 2021-12-09 | Bacterial laccase allosteric and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (8) | CN117210422A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115125220B (en) * | 2022-07-07 | 2024-03-01 | 武汉轻工大学 | Laccase EcLac and application thereof, laccase gene EcLac and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100351382C (en) * | 2004-03-04 | 2007-11-28 | 深圳市构思生物技术有限公司 | Expression carrier of laccase, microorganism strain of expression, laccase protein of expression and application thereof |
US7939307B2 (en) * | 2005-12-02 | 2011-05-10 | National University Corporation Kanazawa University | Deletion mutant of multi-copper oxidase and its use in dyeing |
JP4756601B2 (en) * | 2006-09-05 | 2011-08-24 | 株式会社豊田中央研究所 | Electrocatalyst and enzyme electrode |
CN101955952B (en) * | 2010-08-02 | 2012-05-09 | 安徽大学 | Bacterial laccase gene and expression and application thereof |
JP2014001172A (en) * | 2012-06-20 | 2014-01-09 | Panasonic Corp | A peptide binding to silver |
CN104087560B (en) * | 2013-12-05 | 2016-10-19 | 安徽大学 | Bacterial laccase mutant protein, recombinant expression plasmid thereof, transformed engineering strain and fermentation preparation method thereof |
CN103710317B (en) * | 2013-12-18 | 2015-08-12 | 中国科学院微生物研究所 | A kind of Laccase mutant and encoding gene thereof and application |
CN105176939B (en) * | 2015-09-02 | 2019-01-01 | 北京安生绿源科技有限公司 | A kind of laccase containing unnatural amino acid, preparation method and application |
CN105255843B (en) * | 2015-11-23 | 2019-01-04 | 中国农业科学院生物技术研究所 | Escherichia coli Laccase mutant and its encoding gene and application |
CN106434579A (en) * | 2016-10-17 | 2017-02-22 | 天津科技大学 | Laccase from Klebsiella pneumoniae, as well as recombinant strain and preparation method thereof |
-
2021
- 2021-12-09 CN CN202311195365.XA patent/CN117210422A/en active Pending
- 2021-12-09 CN CN202311195364.5A patent/CN117210421A/en active Pending
- 2021-12-09 CN CN202311195368.3A patent/CN117210424A/en active Pending
- 2021-12-09 CN CN202311195367.9A patent/CN117210423A/en active Pending
- 2021-12-09 CN CN202111496402.1A patent/CN113999826B/en active Active
- 2021-12-09 CN CN202311195369.8A patent/CN117210425A/en active Pending
- 2021-12-09 CN CN202311195362.6A patent/CN117210419A/en active Pending
- 2021-12-09 CN CN202311195363.0A patent/CN117210420A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113999826B (en) | 2023-10-31 |
CN117210419A (en) | 2023-12-12 |
CN113999826A (en) | 2022-02-01 |
CN117210421A (en) | 2023-12-12 |
CN117210424A (en) | 2023-12-12 |
CN117210423A (en) | 2023-12-12 |
CN117210422A (en) | 2023-12-12 |
CN117210425A (en) | 2023-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113528476B (en) | Glucose oxidase mutant and coding gene and efficient recombinant expression thereof | |
CN107794273B (en) | Three-gene co-expression vector for synthesizing DL-alanine and application | |
CN109055324B (en) | Improved ketoreductase and application thereof | |
CN106754775A (en) | A kind of carbonyl reduction enzyme mutant and its gene and application | |
CN113999826B (en) | Bacterial laccase allosteric and preparation method thereof | |
CN113563481A (en) | Aflatoxin B capable of being degraded simultaneously1Construction method and application of mutant of zearalenone fusion enzyme | |
CN104726435A (en) | Beta-glucosidase mutant, recombinant expression plasmid thereof and transformed engineering strain | |
JP7388195B2 (en) | Trichoderma reesei mutant strain and protein production method | |
CN117511831A (en) | Construction method of ergothioneine-producing escherichia coli | |
CN116676296A (en) | Beta-1, 3-glucanase mutants with improved enzymatic activity | |
CN111057695A (en) | Nitrilase and preparation method and application thereof | |
WO2018196881A1 (en) | Glucose oxidase cngoda and gene and application thereof | |
CN112301014B (en) | Esterase mutant with improved thermal stability and application thereof | |
JP7388194B2 (en) | Mutant strain of Trichoderma reesei and method for producing protein using the same | |
WO2020075787A1 (en) | Mutant strain of trichoderma reesei, and protein manufacturing method | |
AU2021100409A4 (en) | Recombinant low-temperature catalase, recombinant vector and engineered strain thereof | |
CN112646791B (en) | Mutant and construction method and application thereof | |
CN114621944B (en) | Arginine deiminase mutant with improved enzyme activity | |
CN107354167A (en) | Efficient degradation grease functional gene carrier and its structure and application | |
CN117247924A (en) | Ame1-FgTad2-FgTad3 editing enzyme system, editing tool and editing method | |
CN118620855A (en) | Mutant of acetaldehyde dehydrogenase and preparation method and application thereof | |
CN116064476A (en) | Non-limiting endonuclease mutant and preparation method thereof | |
CN118272339A (en) | Protein, preparation method and application thereof, biological material and application thereof | |
CN118581065A (en) | LwaCas13a nuclease mutant and preparation method and application thereof | |
CN117844721A (en) | Whole-cell catalyst for efficiently catalyzing and preparing pseudouridine and preparation and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |